{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ozer I"],"funding":["Center for AIDS Research, University of Washington","NIDDK NIH HHS","Center for AIDS Research, Duke University","Army Research Office","National Institutes of Health","School of Medicine, Duke University"],"pagination":["121985"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10918641"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["294"],"pubmed_abstract":["Many biologics have a short plasma half-life, and their conjugation to polyethylene glycol (PEG) is commonly used to solve this problem. However, the improvement in the plasma half-life of PEGylated drugs' is at an asymptote because the development of branched PEG has only had a modest impact on pharmacokinetics and pharmacodynamics. Here, we developed an injectable PEG-like conjugate that forms a subcutaneous depot for the sustained delivery of biologics. The PEG-like conjugate consists of poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) conjugated to exendin, a peptide drug used in the clinic to treat type 2 diabetes. The depot-forming exendin-POEGMA conjugate showed greater efficacy than a PEG conjugate of exendin as well as Bydureon, a clinically approved sustained-relea"],"journal":["Biomaterials"],"pubmed_title":["An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug."],"pmcid":["PMC10918641"],"funding_grant_id":["R01DK124276","W911NF-20-2-0182","R01 DK124276"],"pubmed_authors":["Sirohi P","Collier JH","Campbell JE","D'Alessio DA","Spasojevic I","Chilkoti A","Zakharov N","Everitt JI","Li X","Yao Y","Ozer I","Slezak A","Craig SL"],"additional_accession":[]},"is_claimable":false,"name":"An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug.","description":"Many biologics have a short plasma half-life, and their conjugation to polyethylene glycol (PEG) is commonly used to solve this problem. However, the improvement in the plasma half-life of PEGylated drugs' is at an asymptote because the development of branched PEG has only had a modest impact on pharmacokinetics and pharmacodynamics. Here, we developed an injectable PEG-like conjugate that forms a subcutaneous depot for the sustained delivery of biologics. The PEG-like conjugate consists of poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) conjugated to exendin, a peptide drug used in the clinic to treat type 2 diabetes. The depot-forming exendin-POEGMA conjugate showed greater efficacy than a PEG conjugate of exendin as well as Bydureon, a clinically approved sustained-relea","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-04T12:58:26.732Z","creation":"2025-04-04T12:58:26.732Z"},"accession":"S-EPMC10918641","cross_references":{"pubmed":["36630826"],"doi":["10.1016/j.biomaterials.2022.121985"]}}